| Attribute |
Value |
| 52 Week Change |
-0.2517647 |
| Address1 |
One Corporate Drive |
| Address2 |
2nd Floor |
| All Time High |
937.75 |
| All Time Low |
3.76 |
| Ask |
7.69 |
| Ask Size |
2 |
| Audit Risk |
7 |
| Average Analyst Rating |
1.1 - Strong Buy |
| Average Daily Volume10 Day |
517,660 |
| Average Daily Volume3 Month |
295,350 |
| Average Volume |
295,350 |
| Average Volume10Days |
517,660 |
| Beta |
2.256 |
| Bid |
4.58 |
| Bid Size |
2 |
| Board Risk |
7 |
| Book Value |
5.137 |
| City |
South San Francisco |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
9 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
6.105 |
| Current Ratio |
2.557 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
6.45 |
| Day Low |
5.97 |
| Debt To Equity |
13.693 |
| Display Name |
Aligos Therapeutics |
| Earnings Timestamp |
1,778,184,000 |
| Earnings Timestamp End |
1,786,046,400 |
| Earnings Timestamp Start |
1,786,046,400 |
| Ebitda |
-94,589,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
0.135 |
| Enterprise To Revenue |
-2.716 |
| Enterprise Value |
-12,776,899 |
| Eps Current Year |
-7.10994 |
| Eps Forward |
-3.989 |
| Eps Trailing Twelve Months |
-9.39 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
5.7417 |
| Fifty Day Average Change |
0.36329985 |
| Fifty Day Average Change Percent |
0.063273914 |
| Fifty Two Week Change Percent |
-25.176472 |
| Fifty Two Week High |
13.689 |
| Fifty Two Week High Change |
-7.584 |
| Fifty Two Week High Change Percent |
-0.5540215 |
| Fifty Two Week Low |
4.8 |
| Fifty Two Week Low Change |
1.3049998 |
| Fifty Two Week Low Change Percent |
0.27187496 |
| Fifty Two Week Range |
4.8 - 13.689 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,602,855,000,000 |
| Float Shares |
3,646,349 |
| Forward Eps |
-3.989 |
| Forward P E |
-1.5304587 |
| Free Cashflow |
-48,985,376 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
82 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,782,864,000 |
| Gross Margins |
0.0 |
| Gross Profits |
-64,871,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.10755 |
| Held Percent Institutions |
0.55083 |
| Implied Shares Outstanding |
6,188,223 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,020-10-16 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,724,025,600 |
| Last Split Factor |
1:25 |
| Long Business Summary |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. |
| Long Name |
Aligos Therapeutics, Inc. |
| Market |
us_market |
| Market Cap |
37,779,100 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_581475891 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-90,321,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
39,357,098 |
| Number Of Analyst Opinions |
7 |
| Open |
6.33 |
| Operating Cashflow |
-84,722,000 |
| Operating Margins |
-9.51555 |
| Overall Risk |
8 |
| Payout Ratio |
0.0 |
| Phone |
800 466 6059 |
| Previous Close |
6.36 |
| Price Eps Current Year |
-0.858657 |
| Price Hint |
2 |
| Price To Book |
1.1884369 |
| Price To Sales Trailing12 Months |
8.029564 |
| Profit Margins |
0.0 |
| Quick Ratio |
2.354 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.14286 |
| Region |
US |
| Regular Market Change |
-0.2550001 |
| Regular Market Change Percent |
-4.0094357 |
| Regular Market Day High |
6.45 |
| Regular Market Day Low |
5.97 |
| Regular Market Day Range |
5.97 - 6.45 |
| Regular Market Open |
6.33 |
| Regular Market Previous Close |
6.36 |
| Regular Market Price |
6.105 |
| Regular Market Time |
1,784,059,201 |
| Regular Market Volume |
102,514 |
| Return On Assets |
-0.55556 |
| Return On Equity |
-1.21863 |
| Revenue Growth |
8.1 |
| Revenue Per Share |
0.453 |
| Sand P52 Week Change |
0.20365608 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
8 |
| Shares Outstanding |
5,388,223 |
| Shares Percent Shares Out |
0.087799996 |
| Shares Short |
543,337 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
576,909 |
| Short Name |
Aligos Therapeutics, Inc. |
| Short Percent Of Float |
0.1035 |
| Short Ratio |
6.33 |
| Source Interval |
15 |
| State |
CA |
| Symbol |
ALGS |
| Target High Price |
175.0 |
| Target Low Price |
20.0 |
| Target Mean Price |
56.28571 |
| Target Median Price |
45.0 |
| Total Cash |
54,909,000 |
| Total Cash Per Share |
8.873 |
| Total Debt |
4,353,000 |
| Total Revenue |
4,705,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-9.39 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
7.741975 |
| Two Hundred Day Average Change |
-1.6369748 |
| Two Hundred Day Average Change Percent |
-0.2114415 |
| Type Disp |
Equity |
| Volume |
102,514 |
| Website |
https://www.aligos.com |
| Zip |
94,080 |